Lutikizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Lutikizumab comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hidradenitis Suppurativa. Most recent publication: Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial., JAMA Dermatol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.
    Kimball AB, Sawicki KT, Ackerman L, et al. · JAMA Dermatol · 2026
    PubMed: PMID 41848710 · NCT05139602 · Hidradenitis Suppurativa

Publications by year

20262026: 1 publications.

2026
1

Publications by indication

Hidradenitis Suppurativa (1)

  • Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.
    JAMA Dermatol · 2026 · PMID 41848710 · NCT05139602

Publications by journal

All Lutikizumab publications (1)

2026 (1 paper)

  1. Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.
    Kimball AB, Sawicki KT, Ackerman L, et al. · JAMA Dermatol · 2026 · Derived
    PubMed: PMID 41848710 · NCT05139602 · Hidradenitis Suppurativa

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).